Aerpio Pharmaceuticals, Inc. ARPO Balance Sheet

Aerpio pharmaceuticals, inc. (ARPO)

Balance Sheet / Yearly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Dec'10
Assets
Current assets:
Cash and cash equivalents
34,584	38,524	43,389	48,157	53,422	62,614	68,807	68,783	13,763	20,264	24,828	28,847	35,139	1,609	7	20	13	5,144	6	10	23	5	17	4	5	6	10	18	2	4	5	9	23	4	6	9	26
Short-term investments
-	-	-	-	-	-	-	-	-	-	50	50	50	50	-	-	-	50	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable
-	-	-	-	-	-	-	-	-	-	39	4	32	4	-	-	-	118	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid research and development contracts
228	311	538	368	340	754	337	428	388	313	323	311	297	353	-	-	-	266	-	-	-	-	0	0	0	2	4	0	1	3	5	6	0	2	4	6	2
Other current assets
578	734	876	264	536	615	895	213	457	322	621	431	602	209	-	-	-	386	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total current assets
35,392	39,570	44,804	48,789	54,299	63,984	70,039	69,425	14,610	20,899	25,863	29,644	36,121	2,226	-	-	-	5,965	-	-	-	-	-	-	-	-	-	-	3	-	11	15	24	6	10	15	29
Furniture and equipment, net
149	164	281	297	198	98	101	92	103	107	116	129	138	149	-	-	-	105	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease right-of-use assets, net
138	162	424	472	517	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deposits
20	40	40	40	40	40	20	20	20	20	20	20	20	20	-	-	-	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total assets
35,700	39,936	45,551	49,600	55,056	64,123	70,161	69,538	14,734	21,027	26,001	29,794	36,280	2,396	7	20	13	6,092	6	10	23	5	17	4	6	8	14	18	-	8	-	-	-	-	-	-	-
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses
2,547	3,231	3,403	3,402	3,734	5,456	3,644	2,965	3,622	3,592	2,586	1,856	2,970	2,470	-	-	-	2,159	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current portion of operating lease liability
106	102	197	193	189	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	18,666	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	12,386	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	10	8	-	2	1	10	2	10	8	0	0	0	0	6	1	0	0	3	2	2	2	2
Accrued interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	39	37	34	-	30	28	25	24	22	20	18	17	15	13	12	11	10	8	7	6	-	-	2
Accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	3	3	-	3	3	3	8	3	2	7	5	3	2	1	5	1	1	1	5	7	6	5
Notes payable, stockholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	170	170	160	-	145	145	145	125	125	110	110	110	110	110	85	85	85	85	85	60	60	60	60
Total current liabilities
2,654	3,334	3,601	3,595	3,923	5,456	3,644	21,632	3,622	3,592	2,586	1,856	2,970	14,857	215	220	206	2,159	180	178	184	160	161	141	136	133	129	126	105	103	97	95	97	74	69	68	70
Operating lease liability, net of current portion
39	67	236	288	337	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total liabilities
2,693	3,401	3,837	3,883	4,261	5,456	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Commitments and contingencies (Note 9)
-	-	-	-	-	-	0	0	0	-	0	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Redeemable convertible preferred stock (all classes)
-	-	-	-	-	-	-	-	-	-	-	-	-	73,757	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Redeemable convertible preferred stock (all classes)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	70,487	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Common stock, $0.0001 par value per share; 300,000,000 shares authorized and 40,588,004 shares issued and outstanding at March 31, 2020 and December 31, 2019.
4	4	4	4	4	4	4	3	2	2	2	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Additional paid-in capital
179,156	178,766	179,499	178,853	178,249	177,621	176,953	169,880	127,097	125,995	125,740	125,612	125,465	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49	-	49	49	49	49	49	49	49
Additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	49	49	49	-	49	49	49	49	49	49	49	49	49	49	-	49	-	-	-	-	-	-	-
Accumulated deficit
-146,154	-142,235	-137,789	-133,141	-127,457	-118,959	-110,440	-121,978	-115,988	-108,562	-102,327	-97,678	-92,157	-86,218	-257	-250	-242	-66,554	-224	-218	-210	-205	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deficit accumulated during the development stage
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	193	186	180	174	164	158	151	145	135	129	123	118	109	102	90
Total stockholders’ equity
33,006	36,535	41,714	45,716	50,795	58,666	66,517	47,906	11,111	17,435	23,415	27,937	33,310	-86,218	-207	-200	-192	-66,554	-174	-168	-160	-155	-143	-136	-130	-124	-114	-108	-101	-95	-85	-79	-73	-68	-59	-52	-40
Total liabilities and stockholders’ equity
35,700	39,936	45,551	49,600	55,056	64,123	70,161	69,538	14,734	21,027	26,001	29,794	36,280	2,396	7	20	13	6,092	6	10	23	5	17	4	6	8	14	18	3	8	11	15	24	6	10	15	29